227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study

导出原文传递

翻译打印收藏纠错

作者： Ola Lindén ^[1] ; Andrew T. Bates ^[2] ; David Cunningham ^[3] ; Cecilia Hindorf ^[4] ; Erik Larsson ^[5] ; Adriaan Cleton ^[6] ; Joerg Pinkert ^[7] ; Funan Huang ^[8] ; Friedhelm Bladt ^[9] ; Hartwig Hennekes ^[10] ; Liv-Ingrid Oedegaardstuen ; Isrid Sturm ; Christopher McNamara

作者单位： Department of Oncology, Lund University Hospital ^[1] Research and Development, Bayer AS ^[2] Department of Radiation Physics, Sk?ne University Hospital ^[3] Pharmacovigilance, Benefit-Risk Management Oncology, Bayer AG ^[4] Clinical Oncology Department, University Hospital Southampton NHS Foundation Trust ^[5] Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital ^[6] Strategic Business Unit Oncology, Bayer Healthcare US, Whippany ^[7] Strategic Business Unit Oncology, Bayer AG ^[8] Translational Sciences Asia, Bayer Healthcare Co. Ltd ^[9] Department of Haematology, University College London Hospital ^[10]

关键词 targeted alpha therapy 227Th CD22 first-in-human non-Hodgkin lymphoma

发布时间 2022-03-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交